I’ll have more after the conference call, but Zepatier® sales were slightly behind analysts’ expectations (in testimony to the effects of aggressive price cutting, as I predicted), as were global sales revenues overall.
And while Keytruda® did well in the quarter, BMS’s Opdivo® is clearly pulling away (also as I long predicted). Both are making money hand over fist though, to be fair. Here’s the improved April 2016 currencies translation prediction (which proportionately mirrors the Pfizer experience/effect I mentioned Tuesday — improving from a projected 7 per cent drag on sales, to a far more modest 2 per cent drag, for the full year):
. . . .At mid-April exchange rates, Merck now anticipates full-year 2016 revenues to be between $39.0 billion and $40.2 billion, including an approximately 2 percent negative impact from foreign exchange. . . .
All in all, a solid start to the year — more before too terribly long. G’morning!